Endocrinology
Conference Coverage
Medications provide best risk-to-benefit ratio for weight loss, says expert
Surgery provides the most weight loss, but has the greatest risk, according to an endocrinology, diabetes, and metabolism professor.
From the Journals
Seasonal variation in thyroid hormone TSH may lead to overprescribing
Seasonal differences in thyroid stimulating hormone could in turn lead to overprescribing of thyroxine for hypothyroidism, says lab scientist.
Latest News
Parathyroidectomy does not preserve kidney function in seniors
For adults age 60 or older with primary hyperparathyroidism, preservation of kidney function should not be a primary consideration when making...
Commentary
TikTok offers to ‘balance your hormones’ are pure hokum
TikTok hormone-balancing solutions are simply the 21st-century version of the snake oil sold on late-night cable TV in the 1990s.
From the Journals
Statins don’t worsen muscle injury from moderately intense exercise
Statin users need not limit exercise out of concern that the drugs will worsen normal muscle pain or fatigue, a controlled study suggests.
From the Journals
High salt intake linked to atherosclerosis even with normal BP
Latest News
SGLT2 inhibitors: Real-world data show benefits outweigh risks
“The importance of our paper is that it quantifies the absolute rate of events among routine care patients and may be used to inform shared...
From the Journals
Disparities in statin use persist in high-risk Americans
National database analysis finds disparities in primary-prevention statin use persist despite 10-year atherosclerotic cardiovascular disease risk...
Commentary
What happens when newer weight loss meds are stopped?
Although these drugs are very effective for weight loss and treating diabetes, there can be adverse effects.
From the Journals
Tooth loss and diabetes together hasten mental decline
The findings of a new study show “the importance of improving access to dental health care and integrating primary dental and medical care,”...
News from the FDA/CDC
Prostate cancer drug shortage leaves some with uncertainty
The therapy lutetium Lu 177 vipivotide tetraxetan will remain in limited supply until the drug’s manufacturer can ramp up production.